Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Overstock.com Inc. (NASDAQ:OSTK): The company reported better than expected quarterly results and consequently received rating upgrades from various research companies. Bank of America raised the company’s rating from Neutral to Buy while increasing the price target from $12 to $20. Similarly, Merrill Lynch also raised the rating from Neutral to Buy for Overstock.com.
The stock is currently trading at $19.13, up 2.14 percent. It is trading above its 20 days moving average price of $19.00. The stock oscillated in the range of $18.36 and $19.23 in the current trading session. The company stock’s beta stands at 1.30, implying mildly high volatility. Overstock.com commands the market capitalization of $447.80 million. The stock gained 232.09 percent of its value in the past 52 weeks, while it has gained 36.88 percent in 2013 so far. It has traded in the range of $5.39 and $19.25 in the past 52 weeks.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX): The stock is trading at $83.07, 2.97 percent lower than its previous close. The company recently received positive test results for its cystic fibrosis drug and also gained rating upgrades in the process. Vertex Pharmaceuticals received rating upgrade from Goldman Sachs as it upped the pharma company from Sell to Neutral. Its price target has been raised from $38 to $86. Canaccord Genuity, on the other hand, increased the price target from $55 to $96. Its rating has also been upped from Hold to Buy. The company stock has traded in the range of $82.34 and $87.47 in the current trading session, creating its new 52 weeks high. It has traded 3.54 million shares so far, in comparison to its daily average trading volume of 2.56 million shares. Vertex Pharmaceuticals stock is currently trading below its 20 days moving average price of $83.14. The stock has gained 127.04 percent of its value in the past 52 weeks period. The company stock trades at beta of 0.28, implying low volatility. Vertex Pharmaceuticals’ current market capitalization stands at $18.12 billion.
Coach Inc. (NYSE:COH): The luxury goods company has received a barrage of downgrades. Robert W. Baird downgraded the stock from Outperform to neutral. The research firm stated, “Our annual handbag survey suggests continued market share pressure, which we believe will continue to dampen investor enthusiasm. While positive on Coach’s reinvigorated lifestyle strategy, we expect benefits to take time; similarly, we anticipate the contribution from men’s and international to gradually build.” The stock’s price target was also slashed from $61 to $59. Its stock traded in the range of $50.29 and $24.45 in the current trading session and at this point is at $51.12, down 0.16 percent. Vertex Pharmaceuticals traded 3.19 million shares in this session so far, in comparison to its regular trading volume of 5.71 million. The stock’s highest price point of 52 weeks stands at $51.45 while its lowest price point is at $50.29. Vertex Pharmaceuticals stock is down 32.39 percent in the past 52 weeks while it lost 5.78 percent in 2013 so far. Its stock is trading at Price Earnings ratio of 14.10 and its beta is 1.59. The company’s dividend yield stands at 2.35 percent. Coach stock also downgraded by Citigroup which lowered the rating from Equal Weight to Sell.
Apache Corp. (NYSE:APA): The stock is trading 0.31 percent lower, at $68.63. The stock is currently at its 52 weeks low and has been downgraded by Morgan Stanley from Overweight to Equal Weight. Oppenheimer also lowered the rating for the stock from Outperform to Market Perform. The company has traded 1.74 million shares in the current trading sessions so far and its stock has traded in the range of $67.91 and $98.20 in the past 52 weeks. The stock is down 10.94 percent in the year 2013 so far. The company stock’s beta is 1.36, while its P/E ratio stands at 14.11. Apache Corp. commands market capitalization of $26.88 billion and its stock is currently trading below its 20 days moving average price of $74.33. JPMorgan’s new rating for the stock is at neutral, while its older rating stood at Overweight. However, its new price target has been set at $95. JPMorgan cited the concerns about the growth of the company as the main reason for the downgrade. Its lack of growth catalyst also contributed the rating downgrade.
